 Home > Medical News > Latest Medical News > Submitted a domestic market application for nascentumumab in children with high-risk neuroblastoma

Submitted a domestic market application for nascentumumab in children with high-risk neuroblastoma

 Last Update: 2021-08-08
 Source: Internet
 Author: User

Tags

buprenorphine drug

ice phase diagram

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On July 6, Saisheng Pharmaceutical announced that it had submitted a marketing application for the GD2 monoclonal antibody drug Naxitamab (Naxitamab) to NMPA

Naxitumumab is a humanized monoclonal antibody to ganglioside GD2, which works by targeting GD2 that is highly expressed in neuroblastoma

In the U.

From Y-mabs official website

Neuroblastoma is a malignant tumor of the sympathetic nervous system.

At present, in addition to surgery and radiotherapy, the drugs used to treat neuroblastoma include chemotherapeutic drugs and immunotherapy drugs, with limited treatment options

According to the Insight database, only 3 monoclonal antibody products targeting GD2 to treat neuroblastoma have been approved worldwide

In addition, among the products under development with the same target, in addition to these three monoclonal antibodies, there are four other projects, all of which are CAR-T products in the early clinical stage

Global R&D Overview:

Neuroblastoma treatment drugs targeting GD2

From Insight Global New Drug Library (http://db.

With the two GD2 antibodies of Detuximab and Naxitumumab submitted for NDA in China, it is believed that patients with high-risk neuroblastoma will usher in new treatment options and obtain longer survival benefits

Reference source:

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.